Key Takeaways:
Ascletis Pharma Inc. (HKEX: 1672) completed enrollment of 100 participants in its U.S. Phase 2 clinical trial evaluating ASC30, a once-daily oral drug for the treatment of type 2 diabetes.
"Expanding ASC30's clinical development into the large diabetes treatment market is a logical next step that provides us with another chance to highlight ASC30's potential best-in-class profile," Jinzi Jason Wu, Ph.D., Founder, Chairman and CEO of Ascletis, said in a statement.
The 13-week, randomized, double-blind, and placebo-controlled study is designed to assess the efficacy and safety of ASC30 in adults with type 2 diabetes. The primary endpoint is the change in hemoglobin A1c (HbA1c) levels from baseline compared to placebo. Secondary endpoints include changes in fasting blood glucose and body weight.
The trial's completion of enrollment keeps Ascletis on schedule for a key data release and positions it to challenge established players like Novo Nordisk and Eli Lilly in the multi-billion dollar GLP-1 market, which is currently dominated by injectable therapies. An effective oral option could capture significant market share from patients seeking more convenient treatment regimens.
ASC30 is a small molecule GLP-1 receptor agonist that was discovered and developed in-house by Ascletis. The company is pursuing a dual-indication strategy for the drug, with type 2 diabetes being the second after obesity.
Based on positive results from a Phase 2 study in patients with obesity announced in December 2025, Ascletis expects to get clearance from the U.S. Food and Drug Administration to begin Phase 3 trials for the obesity indication by the end of the third quarter of 2026.
The completion of enrollment is a key operational milestone, keeping the company on track for its 2026 data readout. Investors will be watching for the topline results in Q3 2026 as the next major catalyst to validate the drug's potential against established injectable GLP-1s.
This article is for informational purposes only and does not constitute investment advice.
